Clinical Trial · NCT02825875

Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men With Prostate Cancer

Overview

In this study we aim to more precisely define the clinical utility of PSMA imaging across a range of clinical indications in men with prostate cancer. To accomplish this, we will make the 18F-DCFPyL PET/CT scan available to urologists, medical oncologists, and radiation oncologists at Johns Hopkins and survey physicians as to the indication for ordering the PET/CT and if a change in management occurred as the result of new information gained from the scan. We believe these data will prove critical for planning future studies aimed at evaluating the efficacy of this test for improving patient outcomes.

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Contacts

Michael Gorin, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02825875

Drug / Compound

DCFPyL

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Eligibility

Inclusion

PSA measurement ≤60 days prior to study enrollment
Histologically confirmed adenocarcinoma of the prostate
Completed radiographic evaluation with whole-body bone scan (99mTc-MDP or Na18F) and cross-sectional imaging (CT or MRI) of the abdomen and pelvis ≤60 days prior to study enrollment

Exclusion

Administered a radioisotope within 5 physical half-lives prior to study enrollment